Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18702294 | 0.86 | SPR (0.31) | — | |
| SCHEMBL13002662 | 0.85 | DPP4 (0.44) | DPP4DPP8DPP9ALDH1A1DPP7 | |
| SCHEMBL18307613 | 0.85 | DPP4 (0.44) | DPP4DPP8DPP9ALDH1A1DPP7 | |
| SCHEMBL14804544 | 0.85 | DPP4 (0.44) | DPP4DPP8DPP9ALDH1A1DPP7 | |
| SCHEMBL20469332 | 0.79 | DPP4 (0.40) | DPP4RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL10223227 | 0.79 | LOXL2 (0.30) | DPP4RIPK1MEN1KMT2A | |
| SCHEMBL18427191 | 0.79 | RIPK1 (0.40) | GLRA1DPP4RIPK1DPP8DPP9 | |
| SCHEMBL18702298 | 0.78 | L3MBTL3 (0.34) | DPP4RIPK1MEN1KMT2ADPP8 | |
| SCHEMBL10223225 | 0.78 | RIPK1 (0.34) | RIPK1MEN1KMT2ATACR1HDAC8 | |
| SCHEMBL10223178 | 0.78 | RIPK1 (0.34) | RIPK1MEN1KMT2ATACR1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071721-B2 | Bicyclic amide compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-10933036-B2 | — | — | 2021-03-02 | — | — | US | disclosed |
| US-10336773-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-10011581-B2 | Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180118705-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118705-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130211098-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-08-15 | — | — | US | disclosed |
| US-8481044-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8449890-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | DGAT1, DGAT2, MOGAT2 | GLRA1 308/4885DPP4 342/4885RIPK1 3690/4885 |
| US-20130211098-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUNDS | CYP4B1, P2RX5, MECP2 | GLRA1 912/4885DPP4 676/4885RIPK1 4647/4885 |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GLRA1 668/4885DPP4 66/4885RIPK1 4286/4885 |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GLRA1 732/4885DPP4 67/4885RIPK1 4473/4885 |
| US-10011581-B2 | Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound | CYP4B1, P2RX5, P2RX6 | GLRA1 1023/4885DPP4 637/4885RIPK1 4601/4885 |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | CYP4B1, CYP1B1, AADAC | GLRA1 237/4885DPP4 2775/4885RIPK1 4061/4885 |
| US-11071721-B2 | Bicyclic amide compounds and methods of use thereof | CYP4B1, CYP1B1, AADAC | GLRA1 237/4885DPP4 2775/4885RIPK1 4061/4885 |
| US-20180118705-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUND | CYP4B1, P2RX5, P2RX6 | GLRA1 1023/4885DPP4 637/4885RIPK1 4601/4885 |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | GLRA1 763/4885DPP4 91/4885RIPK1 4173/4885 |
| US-10336773-B2 | Neprilysin inhibitors | MME, REN, ACE | GLRA1 732/4885DPP4 67/4885RIPK1 4473/4885 |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GLRA1 732/4885DPP4 67/4885RIPK1 4473/4885 |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GLRA1 732/4885DPP4 67/4885RIPK1 4473/4885 |
| US-10933036-B2 | — | CYP1B1, CYP4B1, CYP11B2 | GLRA1 726/4885DPP4 2830/4885RIPK1 4591/4885 |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | GLRA1 763/4885DPP4 91/4885RIPK1 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.